Jun 14
Proxy statement
DEFA14A
Proxy statement
HEPA · Hepion Pharmaceuticals, Inc. · Documents
$0.14
-0.18 (-57.55%)
At close · May 13
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Due to our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern within one year of the issuance of these condensed consolidated financial statements without additional capital becoming available to us.”View the 10-Q filed Aug 13, 2026
Market Cap
$6.77M
Shares
90.22M
Volume · May 13
1.91M
Avg daily vol (40 sessions)
7.18M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2022
Jun 6
Current report
8-K
Events of Jun 3
Delisting notice or listing transfer
May 31
Proxy statement
DEFA14A
Proxy statement
May 27
Current report
8-K
Regulation FD disclosure
May 16
Quarterly report
10-Q
FY2022 Q1, ended Mar 31
Quarterly report for FY2022 Q1
Revenue $0
Net loss $6.93M
Diluted EPS -$0.09
Apr 29
Proxy statement
DEF 14A
Meeting Jun 24, 2022
Proxy statement
Apr 20
Proxy statement
PRE 14A
Proxy statement
Apr 8
Annual report
10-K
FY2021, ended Dec 31
Annual report for FY2021
Revenue $0
Net loss $32.72M
Diluted EPS -$0.47
Mar 31
Late filing notice
NT 10-K
Late filing notice
Jan 12
Current report
8-K
Events of Jan 9
Director or officer change, or executive pay
Jan 10
Current report
8-K
Regulation FD disclosure
Jan 6
Current report
8-K
Other events
2021
Dec 21
Current report
8-K
Other events
Nov 30
Current report
8-K
Other events
Nov 19
Registration statement
S-3/A
Registration statement
Nov 16
Current report
8-K
Other events
Nov 15
Quarterly report
10-Q
FY2021 Q3, ended Sep 30
Quarterly report for FY2021 Q3
Revenue $0
Net loss $9.27M
Diluted EPS -$0.12
Nov 10
Current report
8-K
Other events
Oct 8
Current report
8-K
Shareholder vote results
Oct 7
Current report
8-K
Other events
Sep 30
Current report
8-K
Regulation FD disclosure
Sep 29
Current report
8-K
Other events
Sep 13
Current report
8-K
Regulation FD disclosure
Sep 7
Proxy statement
DEF 14A
Meeting Oct 7, 2021
Proxy statement
Aug 23
Current report
8-K
Events of Aug 20
Charter or bylaw amendment, or fiscal year change
Aug 23
Proxy statement
PRE 14A
Meeting Oct 3, 2021
Proxy statement
Aug 16
Quarterly report
10-Q
FY2021 Q2, ended Jun 30
Quarterly report for FY2021 Q2
Revenue $0
Net loss $7.67M
Diluted EPS -$0.10
Jul 26
Current report
8-K
Events of Jul 23
Other events
Jul 13
Current report
8-K
Other events
Jun 25
Current report
8-K
Other events
Jun 25
Proxy statement
DEFA14A
Proxy statement
Jun 9
Current report
8-K
Other events
May 14
Quarterly report
10-Q
FY2021 Q1, ended Mar 31
Quarterly report for FY2021 Q1
Revenue $0
Net loss $6.06M
Diluted EPS -$0.12
May 12
Proxy statement
DEF 14A
Meeting Jun 25, 2021
Proxy statement
May 6
Current report
8-K
Other events
Apr 29
Current report
8-K
Other events
Apr 28
Annual report
10-K/A
Ended Dec 31
Annual report for the period ended Dec 31, 2020
Apr 28
Proxy statement
PRE 14A
Proxy statement
Apr 2
Registration statement
S-3
Registration statement
Mar 31
Mar 23
Current report
8-K
Other events
Mar 11
Current report
8-K
Other events
Feb 17
Current report
8-K
Events of Feb 12
Entered into a material agreement, Unregistered sale of equity, Other events
Feb 10
Current report
8-K
Events of Feb 9
Other events
Jan 28
Current report
8-K
Regulation FD disclosure
Jan 5
Current report
8-K
Other events
2020
Dec 29
Current report
8-K
Other events
Dec 22
Current report
8-K
Other events
Dec 10
Current report
8-K
Other events
Dec 2
Current report
8-K
Other events
Showing 101–150 of 197 documents